Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Antibody Targeting Boosts Liposomal Drug Anticancer Activity

Abstract:
The first drug-loaded nanoparticle approved to treat cancer is in line for an upgrade. Researchers at Northeastern University have improved the tumor-killing activity of liposomal doxorubicin, known as Doxil™, by attaching a monoclonal antibody that recognizes a protein found on the surface of cancer cells. The resulting targeted liposome improves drug uptake by malignant cells and, more importantly, increases the potency of the original liposome by as much as eightfold. This work is reported in the European Journal of Pharmaceutical Sciences.

Antibody Targeting Boosts Liposomal Drug Anticancer Activity

Bethesda , MD | Posted on December 5th, 2007

To target liposomal doxorubicin, Vladimir Torchilin, Ph.D., and former graduate student Tamer Elbayoumi, Ph.D., used a monoclonal antibody discovered a decade ago by Torchilin and his colleagues. This antibody binds to a protein found in nucleosomes, a protein-DNA construct that organizes the chromosomes of all multicellular organisms, including humans. In healthy cells, nucleosomes are found only in the cell nucleus, but a broad variety of cancer cells contain a receptor on the cell membrane that recognizes nucleosomes. This particular monoclonal antibody, named mAb 2C5, recognizes and binds to that same receptor, while showing no propensity to bind to healthy cells. Each modified liposome contains approximately 70 to 80 surface-attached monoclonal antibodies.

Tests using a wide range of cultured tumor cells showed that mAb 2C5-targeted liposomal doxorubicin bound avidly to the cells. More importantly, uptake by those cells was rapid, far faster than with untargeted Doxil™ or Doxil™ modified with a control antibody that does not recognize tumor cells. Similarly, the targeted formulation was far more toxic toward all seven tumor cell lines tested, as it was in one preliminary in vivo study using a mouse xenograft model of human cancer. In addition, the investigators found that the targeted formulation, but not plain Doxil™, was also effective at killing a colon cancer cell line that is normally resistant to both Doxil™ and free doxorubicin.

This work is detailed in the paper "Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines." An abstract of this paper is available through PubMed.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

Copyright © National Cancer Institute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

View abstract

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Discoveries

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Announcements

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project